Is anyone familiar with H.R. 485? It has been introduced in the House, but it is not yet law.
According to the CRS “This bill prohibits all federal health care programs, including the Federal Employees Health Benefits Program, and federally funded state health care programs (e.g., Medicaid) from using prices that are based on quality-adjusted life years (i.e., measures that discount the value of a life based on disability) to determine relevant thresholds for coverage, reimbursements, or incentive programs”.
I think the motivation might be to prevent discrimination against people with disabilities, but it seems to me like it goes too far.
It seems to me it would prevent the use of QALYs for making decisions such as is a particular cure for blindness worthwhile, and how might it compare to treatments for other diseases and conditions.
Is anyone familiar with this bill and able to shed more light on it?
I don’t know a lot about this bill specifically, but here’s my sense:
This bill has been pushed by disability activists, who are opposed to things like QALYs, which they consider ableist. Steve Pearson nicely summarizes why here:
This bill currently has no democratic co-sponsors in the House (although this article says that there is “bipartisan interest”), and I do not think it has been introduced in the Senate. Thus, I suspect this bill is unlikely to get passed under a democratic administration, but I’m not sure about that.
Here is some background:
US health care spending is out of control ($4.3 trillion; 18.3% of GDP in 2021); this is a massive, intractable problem, and this bill would certainly not help.
I do not think QALYs are super widely used in the US health care system as is. H.R. 485 represents an expansion of existing restrictions (see page 47) on the use of cost-effectiveness analysis in Medicare and other federal programs; the goal of this legislation is to fully ban the use of QALYs across all federal programs, which I think would include state Medicaid programs, since Medicaid is jointly financed by states and the federal government.
Even in the absence of this bill, there is significant public opposition to the use of QALYs and similar metrics in US health care. (Health care rationing remains a very loaded issue in US politics.)
In terms of things that are wrong with the US health care system, failure to use QALYs is a problem, but I think other things are bigger contributors to the widespread provision of low-value care.
If this bill were to pass, I think (?) it’d still be possible to use things like evLYGs, which could play a similar role as QALYs in cost-effectiveness analysis, but “evenly measure any gains in length of life, regardless of the treatment’s ability to improve patients’ quality of life.”
Tl;dr: I think passing this bill might be akin to shooting holes in the tires of a car that only had two wheels to begin with, and it currently looks unlikely to pass.
If it makes you feel any better, 90-95% of bills are never passed into law.
I don’t have any additional information about this specific bill, but I’d guess that prevention of discrimination is exactly the point.
Yeah, I think this is probably a good thing—QALY-based prices probably shouldn’t be used to determine “determine relevant thresholds for coverage, reimbursements, or incentive programs” (ETA: particularly for federal programs in a health care system like that in the US).
I’m not sure this would come into play here, since insurance coverage etc. (which, to my understanding, is what is in question here) doesn’t operate with that logic, but I could be lacking in imagination.